Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1986 Nov;83(22):8764–8768. doi: 10.1073/pnas.83.22.8764

Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.

A V Schally, A I Kook, E Monje, T W Redding, J I Paz-Bouza
PMCID: PMC387012  PMID: 2946045

Abstract

The combination of hormonal treatment based on a long-acting delivery system for the agonist [6-D-tryptophan]luteinizing hormone-releasing hormone ([D-Trp6]-LH-RH) with the chemotherapeutic agent Novantrone (mitoxantrone dihydrochloride) was studied in the Dunning R3327H rat prostate cancer model. Microcapsules of [D-Trp6]-LH-RH formulated from poly(DL-lactide-co-glycolide) and calculated to release a controlled dose of 25 micrograms/day were injected intramuscularly once a month. Novantrone (0.25 mg/kg) was injected intravenously once every 3 weeks. Three separate experiments were carried out. When the therapy was started 45 days after transplantation and continued for 70 days, tumor volume in the presence of the microcapsules (966 +/- 219 mm3) or Novantrone (3606 +/- 785 mm3) given alone was significantly decreased compared to controls (14,476 +/- 3045 mm3). However, the combination of microcapsules and Novantrone caused a greater inhibition of tumor growth (189 +/- 31 mm3) than the single agents. Similar effects were seen when the percent increase in tumor volume was examined. Tumor volume increased 10,527 +/- 1803% for the control group. The inhibition of growth caused by the [D-Trp6]LH-RH microcapsules alone (672 +/- 153% increase in volume) was again greater than that caused by Novantrone alone (2722 +/- 421% increase). The combination of the two agents was again the most effective, resulting in an increase in tumor volume of only 105 +/- 29%. Control tumors weighed 30.0 +/- 6.5 g. Tumor weights were much less in the groups treated with either microcapsules (3.28 +/- 0.69 g) or Novantrone (19.53 +/- 3.3 g) alone. The lowest tumor weights after 70 days of treatment were obtained in the group that received the combination of [D-Trp6]LH-RH microcapsules and Novantrone (1.02 +/- 0.2 g). Testes and ventral prostate weights were significantly diminished by the administration of microcapsules of [D-Trp6]LH-RH alone or in combination with Novantrone. In both of these groups, luteinizing hormone and prolactin levels were reduced and serum testosterone was suppressed to undetectable levels. Similar results were obtained in two other experiments in which the duration of treatment was 60 or 105 days. These results suggest that the overall response could reflect the inhibition of proliferation of hormone-independent cancer cells by Novantrone in addition to the suppressive effect of [D-Trp6]LH-RH on the growth of androgen-dependent tumor cells. The administration of Novantrone in combination with microcapsules of [D-Trp6]LH-RH might produce a better clinical response than LH-RH analog alone in patients with advanced prostate carcinoma.

Full text

PDF
8764

Images in this article

8767Image
on p.8767
8767Image
on p.8767

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed S. R., Brooman P. J., Shalet S. M., Howell A., Blacklock N. J., Rickards D. Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms. Lancet. 1983 Aug 20;2(8347):415–419. doi: 10.1016/s0140-6736(83)90387-2. [DOI] [PubMed] [Google Scholar]
  2. Allen J. M., O'Shea J. P., Mashiter K., Williams G., Bloom S. R. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist. Br Med J (Clin Res Ed) 1983 May 21;286(6378):1607–1609. doi: 10.1136/bmj.286.6378.1607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Asch R. H., Rojas F. J., Bartke A., Schally A. V., Tice T. R., Klemcke H. G., Siler-Khodr T. M., Bray R. E., Hogan M. P. Prolonged suppression of plasma LH levels in male rats after a single injection of an LH-RH agonist in poly(DL-lactide-co-glycolide) microcapsules. J Androl. 1985 Mar-Apr;6(2):83–88. doi: 10.1002/j.1939-4640.1985.tb00821.x. [DOI] [PubMed] [Google Scholar]
  4. Comaru-Schally A. M., Ramalho A., Leitao P. R., Schally A. V. Clearance of lung metastases of prostate carcinoma after treatment with LH-RH agonist. Lancet. 1984 Aug 4;2(8397):281–282. doi: 10.1016/s0140-6736(84)90319-2. [DOI] [PubMed] [Google Scholar]
  5. Durr F. E. Biologic and biochemical effects of mitoxantrone. Semin Oncol. 1984 Sep;11(3 Suppl 1):3–10. [PubMed] [Google Scholar]
  6. Durr F. E., Wallace R. E., Citarella R. V. Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev. 1983 Dec;10 (Suppl B):3–11. doi: 10.1016/0305-7372(83)90016-6. [DOI] [PubMed] [Google Scholar]
  7. Geller J., Albert J. D. Comparison of various hormonal therapies for prostatic carcinoma. Semin Oncol. 1983 Dec;10(4 Suppl 4):34–41. [PubMed] [Google Scholar]
  8. Gonzalez-Barcena D., Perez-Sanchez P., Berea-Dominguez H., Graef-Sanchez A., Becerril-Morales M., Comaru-Schally A. M., Schally A. V. Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH. Prostate. 1986;9(2):207–215. doi: 10.1002/pros.2990090211. [DOI] [PubMed] [Google Scholar]
  9. Gonzalez-Barcena D., Perez-Sanchez P., Ureta-Sanchez S., Berea Dominguez H., Graef-Sanchez A., Becerril Morales M., Comaru-Schally A. M., Schally A. V. Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH. Prostate. 1985;7(1):21–30. doi: 10.1002/pros.2990070104. [DOI] [PubMed] [Google Scholar]
  10. Isaacs J. T., Coffey D. S. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res. 1981 Dec;41(12 Pt 1):5070–5075. [PubMed] [Google Scholar]
  11. Isaacs J. T. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate. 1984;5(1):1–17. doi: 10.1002/pros.2990050102. [DOI] [PubMed] [Google Scholar]
  12. Janik P., Briand P., Hartmann N. R. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res. 1975 Dec;35(12):3698–3704. [PubMed] [Google Scholar]
  13. Labrie F., Dupont A., Belanger A., Lacoursiere Y., Raynaud J. P., Husson J. M., Gareau J., Fazekas A. T., Sandow J., Monfette G. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate. 1983;4(6):579–594. doi: 10.1002/pros.2990040605. [DOI] [PubMed] [Google Scholar]
  14. Mason-Garcia M., Vigh S., Comaru-Schally A. M., Redding T. W., Somogyvari-Vigh A., Horvath J., Schally A. V. Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations. Proc Natl Acad Sci U S A. 1985 Mar;82(5):1547–1551. doi: 10.1073/pnas.82.5.1547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Mathé G., Vo Van M. L., Duchier J., Misset J. L., Morin P., Keiling R., Schwarzenberg L., Kerbrat P., Achille E., Tronc J. C. An oriented phase-II trial of D-Trp6-LH-RH in patients with prostatic carcinoma. Med Oncol Tumor Pharmacother. 1984;1(2):119–122. doi: 10.1007/BF02934983. [DOI] [PubMed] [Google Scholar]
  16. Mukamel E., Nissenkorn I., Servadio C. Early combined hormonal and chemotherapy for metastatic carcinoma of prostate. Urology. 1980 Sep;16(3):257–260. doi: 10.1016/0090-4295(80)90037-0. [DOI] [PubMed] [Google Scholar]
  17. Murphy G. P., Beckley S., Brady M. F., Chu T. M., deKernion J. B., Dhabuwala C., Gaeta J. F., Gibbons R. P., Loening S. A., McKiel C. F. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer. 1983 Apr 1;51(7):1264–1272. doi: 10.1002/1097-0142(19830401)51:7<1264::aid-cncr2820510716>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  18. Neidhart J. A., Gochnour D., Roach R. W., Young D., Steinberg J. A. A comparative trial of mitoxantrone and doxorubicin in patients with minimally pretreated breast cancer. Semin Oncol. 1984 Sep;11(3 Suppl 1):11–14. [PubMed] [Google Scholar]
  19. Parmar H., Phillips R. H., Lightman S. L., Edwards L., Allen L., Schally A. V. Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet. 1985 Nov 30;2(8466):1201–1205. doi: 10.1016/s0140-6736(85)90739-1. [DOI] [PubMed] [Google Scholar]
  20. Plotka E. D., Seal U. S., Letellier M. A., Verme L. J., Ozoga J. J. Early effects of pinealectomy on LH and testosterone secretion in white-tailed deer. J Endocrinol. 1984 Oct;103(1):1–7. doi: 10.1677/joe.0.1030001. [DOI] [PubMed] [Google Scholar]
  21. Redding T. W., Schally A. V. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1981 Oct;78(10):6509–6512. doi: 10.1073/pnas.78.10.6509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Redding T. W., Schally A. V., Tice T. R., Meyers W. E. Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules. Proc Natl Acad Sci U S A. 1984 Sep;81(18):5845–5848. doi: 10.1073/pnas.81.18.5845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Roger M., Chaussain J. L., Berlier P., Bost M., Canlorbe P., Colle M., Francois R., Garandeau P., Lahlou N., Morel Y. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules. J Clin Endocrinol Metab. 1986 Apr;62(4):670–677. doi: 10.1210/jcem-62-4-670. [DOI] [PubMed] [Google Scholar]
  24. Schally A. V., Comaru-Schally A. M., Redding T. W. Antitumor effects of analogs of hypothalamic hormones in endocrine-dependent cancers. Proc Soc Exp Biol Med. 1984 Mar;175(3):259–281. doi: 10.3181/00379727-175-41797. [DOI] [PubMed] [Google Scholar]
  25. Schally A. V., Redding T. W., Comaru-Schally A. M. Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH. Prostate. 1983;4(6):545–552. doi: 10.1002/pros.2990040602. [DOI] [PubMed] [Google Scholar]
  26. Schally A. V., Redding T. W. Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model. Proc Natl Acad Sci U S A. 1985 Apr;82(8):2498–2502. doi: 10.1073/pnas.82.8.2498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Schmidt J. D., Scott W. W., Gibbons R., Johnson D. E., Prout G. R., Jr, Loening S., Soloway M., deKernion J. B., Pontes J. E., Slack N. H. Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer. 1980 Apr 15;45(7 Suppl):1937–1946. [PubMed] [Google Scholar]
  28. Smith I. E. Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev. 1983 Jun;10(2):103–115. doi: 10.1016/0305-7372(83)90008-7. [DOI] [PubMed] [Google Scholar]
  29. Tolis G., Ackman D., Stellos A., Mehta A., Labrie F., Fazekas A. T., Comaru-Schally A. M., Schally A. V. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A. 1982 Mar;79(5):1658–1662. doi: 10.1073/pnas.79.5.1658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Torti F. M., Carter S. K. The chemotherapy of prostatic adenocarcinoma. Ann Intern Med. 1980 May;92(5):681–689. doi: 10.7326/0003-4819-92-5-681. [DOI] [PubMed] [Google Scholar]
  31. Walker K. J., Nicholson R. I., Turkes A. O., Turkes A., Griffiths K., Robinson M., Crispin Z., Dris S. Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma. Lancet. 1983 Aug 20;2(8347):413–415. doi: 10.1016/s0140-6736(83)90386-0. [DOI] [PubMed] [Google Scholar]
  32. Warner B., Worgul T. J., Drago J., Demers L., Dufau M., Max D., Santen R. J. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer. J Clin Invest. 1983 Jun;71(6):1842–1853. doi: 10.1172/JCI110940. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Waxman J. H., Wass J. A., Hendry W. F., Whitfield H. N., Besser G. M., Malpas J. S., Oliver R. T. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer. Br Med J (Clin Res Ed) 1983 Apr 23;286(6374):1309–1312. doi: 10.1136/bmj.286.6374.1309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Zorn J. R., Tanger C., Roger M., Grenier J., Comaru-Schally A. M., Schally A. V. Therapeutic hypogonadism induced by a delayed-release preparation of microcapsules of D-Trp-6-luteinizing hormone-releasing hormone: a preliminary study in eight women with endometriosis. Int J Fertil. 1986 Mar-Apr;31(1):11-3, 16-27. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES